Stay updated on Tesofensine/Metoprolol in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the Tesofensine/Metoprolol in Type 2 Diabetes Clinical Trial page.

Latest updates to the Tesofensine/Metoprolol in Type 2 Diabetes Clinical Trial page
- CheckyesterdayChange DetectedA MedlinePlus Genetics-related listing for type 2 diabetes was removed, and the site revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe record presents details of the completed Phase 2 study of tesofensine/metoprolol for adults with type 2 diabetes, including its eligibility criteria, treatment arms, outcomes, and posted study documents.SummaryDifference44%

- Check22 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error rather than a study record.SummaryDifference0.2%

- Check29 days agoChange DetectedA banner announces NIH’s transition-related terminology update, including the use of “Super Intelligence” in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check36 days agoChange DetectedThe footer’s site revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check43 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Tesofensine/Metoprolol in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tesofensine/Metoprolol in Type 2 Diabetes Clinical Trial page.